GDC-6036 (Divarasib), another covalent KRAS G12C inhibitor, is ongoing investigated in phase 1 clinical trial for various solid tumours as both monotherapy and in combination with other anti-cancer therapies [46]. This evidence concerns the gene KRAS and cancer.